{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:20:22Z","timestamp":1788841222152,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40262-019-00820-x","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T05:48:46Z","timestamp":1570168126000},"page":"359-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Population Pharmacokinetic and Exposure\u2013Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type\u00a02 Diabetes with Chronic Kidney Disease"],"prefix":"10.1007","volume":"59","author":[{"given":"Nelleke","family":"Snelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Garmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"issue":"3","key":"820_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"820_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403.","journal-title":"ChemMedChem"},{"issue":"1","key":"820_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"31","key":"820_CR4","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"9","key":"820_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"4","key":"820_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complic. 2017;31(4):758\u201365.","journal-title":"J Diabetes Complic"},{"issue":"2","key":"820_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"820_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"820_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-019-00547-x","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019. \nhttps:\/\/doi.org\/10.1007\/s13318-019-00547-x\n\n.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"820_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"820_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","volume":"43","author":"R Heinig","year":"2018","unstructured":"Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the Novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"820_CR12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Heerspink","year":"2015","unstructured":"Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26(8):2055\u201364.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"820_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.kint.2016.09.037","volume":"91","author":"JJ Carrero","year":"2017","unstructured":"Carrero JJ, Grams ME, Sang Y, Arnlov J, Gasparini A, Matsushita K, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91(1):244\u201351.","journal-title":"Kidney Int"},{"issue":"2","key":"820_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115\u201327.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"820_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128\u201339.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"820_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","volume":"53","author":"KM Jamsen","year":"2014","unstructured":"Jamsen KM, McLeay SC, Barras MA, Green B. Reporting a population pharmacokinetic-pharmacodynamic study: a journal\u2019s perspective. Clin Pharmacokinet. 2014;53(2):111\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"820_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000371497","volume":"40","author":"LM Ruilope","year":"2014","unstructured":"Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6):572\u201381.","journal-title":"Am J Nephrol"},{"issue":"4","key":"820_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"6","key":"820_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"820_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s00125-008-1086-9","volume":"51","author":"RA Chudleigh","year":"2008","unstructured":"Chudleigh RA, Ollerton RL, Dunseath G, Peter R, Harvey JN, Luzio S, et al. Performance of the revised \u2018175\u2019 Modification of Diet in Renal Disease equation in patients with type 2 diabetes. Diabetologia. 2008;51(9):1714\u20138.","journal-title":"Diabetologia"},{"issue":"9","key":"820_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"1","key":"820_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56(1):32\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"820_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"issue":"6","key":"820_CR24","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309\u201320.","journal-title":"Kidney Int"},{"issue":"8","key":"820_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921\u20137.","journal-title":"Circulation"},{"issue":"3","key":"820_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2011.132","volume":"80","author":"MR Weir","year":"2011","unstructured":"Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int. 2011;80(3):235\u20137.","journal-title":"Kidney Int"},{"issue":"3","key":"820_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00820-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T23:55:45Z","timestamp":1601682945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00820-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"4 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This publication and the work involved were funded by Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NS and HJD were paid consultants for Bayer AG during the conduct of the analysis. RH, AJ, PK, JL, DG, BP, and TE are employed by Bayer AG. RH, AJ, JL, DG, BP, and TE are Bayer AG shareholders.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}